Impact of metabolic syndrome on lower urinary tract symptoms in patients with benign prostate hyperplasia

  • Dyandra Parikesit Urology Medical Staff Group, Universitas Indonesia Hospital, Universitas Indonesia, Depok, West Java, Indonesia http://orcid.org/0000-0001-5779-2713
  • Fiastuti Witjaksono Department of Nutrition, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Chaidir Arif Mochtar Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Nur Rasyid Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Agus Rizal Ardy Hariandy Hamid Department of Urology, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia
DOI: https://doi.org/10.13181/mji.oa.214256
Keywords: benign prostate hyperplasia, lower urinary tract symptoms, metabolic syndrome
Abstract viewed: 1283 times
PDF downloaded: 584 times
HTML downloaded: 132 times
EPUB downloaded: 170 times

Abstract

BACKGROUND Studies evaluating the relationship between metabolic syndrome (MetS) and lower urinary tract symptoms (LUTS) in men with benign prostate hyperplasia (BPH) are lacking in Indonesia. This study aimed to discover the association of LUTS and MetS in men with BPH.

METHODS Subjects who underwent biopsy were recruited from Cipto Mangunkusumo Hospital, Jakarta, Indonesia from January 2014 to January 2018, but only men who had biopsy-proven BPH were included. Body mass index, waist circumference, fasting blood glucose, triglyceride, high-density lipoprotein, prostate volume (PV), and international prostate symptom score (IPSS) were collected before the biopsy. MetS criteria were based on the National Cholesterol Education Program Adult Treatment Panel III. IPSS was assessed for LUTS and consisted of irritative and obstructive symptoms and quality of life (QoL). Independent t-test or Mann–Whitney test was used to analyze numerical data.

RESULTS Of 227 men with biopsy-proven BPH, 87 (38.3%) were diagnosed with MetS. PV was similar in men with or without MetS (54.4 [20.3–100] versus 49.9 [19.5–100] cm3, p = 0.239). Men with MetS generally had more LUTS (15 [1–30] versus 11 [0–35], p = 0.005), more irritative symptoms (8 [0–20] versus 6 [0–20], p = 0.007), and lower QoL (4 [0–6] versus 3 [0–6], p = 0.018).

CONCLUSIONS BPH patients with MetS had greater LUTS, particularly irritative symptoms and QoL score.

Downloads

Download data is not yet available.

References

  1. Park YW, Kim SB, Kwon H, Kang HC, Cho K, Lee KI, et al. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome. Urology. 2013;82(3):674-9. https://doi.org/10.1016/j.urology.2013.03.047

  2. Rył, A, Rotter I, Miazgowski T, Słojewski M, Dołęgowska B, Lubkowska A, et al. Metabolic syndrome and benign prostatic hyperplasia: association or coincidence? Diabetol Metab Syndr. 2015;7:94. https://doi.org/10.1186/s13098-015-0089-1

  3. Lee SW, Chan EM, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. Sci Rep. 2017;7(1):7984. https://doi.org/10.1038/s41598-017-06628-8

  4. Soewondo P, Purnamasari D, Oemardi M, Waspadji S, Soegondo S. Prevalence of metabolic syndrome using NCEP/ATP III criteria in Jakarta, Indonesia: the Jakarta primary non-communicable disease risk factors surveillance 2006. Acta Med Indones. 2010;42(4):199-203.

  5. Herningtyas EH, Ng TS. Prevalence and distribution of metabolic syndrome and its components among provinces and ethnic groups in Indonesia. BMC Public Health. 2019;19(1):377. https://doi.org/10.1186/s12889-019-6711-7

  6. Parikesit D, Mochtar CA, Umbas R, Hamid AR. The impact of obesity towards prostate diseases. Prostate Int. 2016;4(1):1-6. https://doi.org/10.1016/j.prnil.2015.08.001

  7. Monoarfa RA, Mochtar CA. Validation of indonesian version of IPSS. Indones J Urol. 2014;21(1):15-9. https://doi.org/10.32421/juri.v21i1.20

  8. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52. https://doi.org/10.1161/CIRCULATIONAHA.105.169405

  9. Ohgaki K, Hikima N, Horiuchi K, Kondo Y. Association between metabolic syndrome and male lower urinary tract symptoms in Japanese subjects using three sets of criteria for metabolic syndrome and International Prostate Symptom Score. Urology. 2011;77(6):1432-8. https://doi.org/10.1016/j.urology.2010.12.024

  10. Kim JM, Song PH, Kim HT, Moon KH. Effect of obesity on prostate-specific antigen, prostate volume, and international prostate symptom score in patients with benign prostatic hyperplasia. Korean J Urol. 2011;52(6):401-5. https://doi.org/10.4111/kju.2011.52.6.401

  11. Favilla V, Cimino S, Castelli T, Madonia M, Barbagallo I, Morgia G. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. BJU Int. 2010;106(11):1700-3. https://doi.org/10.1111/j.1464-410X.2010.09459.x

  12. Lepor H. Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol. 2005;7(Suppl 4):S3-12.

  13. Wang JY, Fu YY, Kang DY. The association between metabolic syndrome and characteristics of benign prostatic hyperplasia: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(19):e3243. https://doi.org/10.1097/MD.0000000000003243

  14. Pan JG, Liu M, Zhou X. Relationship between lower urinary tract symptoms and metabolic syndrome in a Chinese male population. J Endocrinol Invest. 2014;37(4):339-44. https://doi.org/10.1007/s40618-013-0018-9

  15. Joseph MA, Wei JT, Harlow SD, Cooney KA, Dunn RL, Jaffe CA, et al. Relationship of serum sex-steroid hormones and prostate volume in African American men. Prostate. 2002;53(4):322-9. https://doi.org/10.1002/pros.10154

  16. Nandeesha H. Benign prostatic hyperplasia: dietary and metabolic risk factors. Int Urol Nephrol. 2008;40(3):649-56. https://doi.org/10.1007/s11255-008-9333-z

  17. Blankstein U, Chughtai B, Elterman DS. Relationship between the metabolic syndrome and BPH-related voiding dysfunction. Curr Bladder Dysfunct Rep. 2014;9:122-8. https://doi.org/10.1007/s11884-014-0230-2

  18. Nicholson TM, Ricke WA. Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 2011;82(4-5):184-99. https://doi.org/10.1016/j.diff.2011.04.006

  19. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes. 2005;29(3):310-6. https://doi.org/10.1038/sj.ijo.0802881

  20. Hammarsten J, Damber JE, Karlsson M, Knutson T, Ljunggren O, Ohlsson C, et al. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2009;12(2):160-5. https://doi.org/10.1038/pcan.2008.50

  21. Hong GS, Shim BS, Chung WS, Yoon H. Correlation between metabolic syndrome and lower urinary tract symptoms of males and females in the aspect of gender-specific medicine: a single institutional study. Korean J Urol. 2010;51(9):631-5. https://doi.org/10.4111/kju.2010.51.9.631

  22. Wang S, Mao Q, Lin Y, Wu J, Wang X, Zheng X, et al. Body mass index and risk of BPH: a meta-analysis. Prostate Cancer Prostatic Dis. 2012;15(3):265-72. https://doi.org/10.1038/pcan.2011.65

  23. Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008;17(11):3252-61. https://doi.org/10.1158/1055-9965.EPI-08-0609

  24. Wang H, Wang J, Liu MM, Wang D, Liu YQ, Zhao Y, et al. Epidemiology of general obesity, abdominal obesity and related risk factors in urban adults from 33 communities of northeast china: the CHPSNE study. BMC Public Health. 2012;12:967. https://doi.org/10.1186/1471-2458-12-967

  25. Saboya PP, Bodanese LC, Zimmermann PR, da Silva Gustavo A, Assumpção CM, Londero F. Metabolic syndrome and quality of life: a systematic review. Rev Lat Am Enfermagem. 2016;24:e2848. https://doi.org/10.1590/1518-8345.1573.2848

  26. Kupelian V, Wei JT, O'Leary MP, Kusek JW, Litman HJ, Link CL, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) survey. Arch Intern Med. 2006;166(21):2381-7. https://doi.org/10.1001/archinte.166.21.2381

  27. Liao L, Chuang YC, Liu SP, Lee KS, Yoo TK, Chu R, et al. Effect of lower urinary tract symptoms on the quality of life and sexual function of males in China, Taiwan, and South Korea: subgroup analysis of a cross-sectional, population-based study. Low Urin Tract Symptoms. 2019;11(2):O78-84. https://doi.org/10.1111/luts.12220

  28. Doğan Y, Uruç F, Aras B, Şahin A, Kıvrak M, Ürkmez A, et al. The relationships between metabolic syndrome, erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia. Turk J Urol. 2015;41(1):7-12. https://doi.org/10.5152/tud.2015.99997

Published
2021-06-30
How to Cite
1.
Parikesit D, Witjaksono F, Mochtar CA, Rasyid N, Hamid ARAH. Impact of metabolic syndrome on lower urinary tract symptoms in patients with benign prostate hyperplasia. Med J Indones [Internet]. 2021Jun.30 [cited 2024Jul.3];30(2):138-42. Available from: http://mji.ui.ac.id/journal/index.php/mji/article/view/4256
Issue
Vol. 30 No. 2 (2021): June
Section
Clinical Research

Copyright (c) 2021 Dyandra Parikesit, Fiastuti Witjaksono, Chaidir Arif Mochtar, Nur Rasyid, Agus Rizal Ardy Hariandy Hamid

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with Medical Journal of Indonesia agree to the following terms:

  1. Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
  2. Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.

Most read articles by the same author(s)